Clinical trials: Early Alzheimers Disease
Alzheimer Disease, Mild Cognitive Impairment
BioFINDER-Brown: Examination of Alzheimer's Disease Biomarkers
This research study aims to examine biomarkers of Alzheimer's disease as early as possible which could potentially be a screening tool for the general population.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Dementia
- Trial name
- NCT05457998
- Testing
- Flutemetamol F18 Injection, [18F]-RO6958948 Injection, [18F]-MK-6240 Injection
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Butler Hospital
Alzheimer's Disease
An Observational Study of LEQEMBI in Routine Clinical Practice in Taiwan
The primary purpose of this study is to describe the incidence and severity of known adverse events, including amyloid-related imaging abnormalities (ARIA)-oedema/effusion (ARIA-E), ARIA-microhemorrhage and haemosiderin deposit…
- Trial name
- NCT07869264
- Testing
- No Intervention
- Where
- 12 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Eisai Taiwan Inc.
Alzheimer's Disease
Effect of Exercises Training in Patients With Mild Cognitive Impairment and Early Alzheimer's Disease
Recent studies have shown that aerobic exercises and dual-task training are effective in improving overall cognitive function in patients with cognitive impairment or dementia.
- Trial name
- NCT02074215
- Testing
- Aerobic exercises, Stretch exercise
- Where
- Taiwan
- Volunteers
- 19 people
- Sponsor
- National Taiwan University Hospital
Mild Cognitive Impairment, Alzheimer Disease
INTERCEPTOR Project: From MCI to Dementia
In the next years a number of phase 2-3 trials which utilize experimental drugs possibly disease modifying for Alzheimer Dementia will reach their conclusion.
- Trial name
- INTERCEPTOR (NCT03834402)
- Where
- Italy
- Volunteers
- 500 people
- Sponsor
- Catholic University of the Sacred Heart
Alzheimer's Disease, MCI-AD, Early Stage Alzheimer's Disease
Efficacy and Safety of Conventional Symptomatic Drugs Combined with Lencanizumab in the Treatment of Early Alzheimer's Disease: a Multicenter, Prospective, Observational Study
According to the World Health Organization, China will become the "oldest" country in the world by 2050, with 35 percent of the elderly population.
- Trial name
- NCT06868030
- Volunteers
- 120 people
- Sponsor
- First Hospital of China Medical University
Alzheimer Disease
Cognitive-Behavioral Treatment for Mild Alzheimer's Patients and Their Caregivers
The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild…
- Trial name
- CBTAC (NCT01273272)
- Testing
- Comprehensive, CBT-based, multi-component treatment, Treatment as usual
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Mild Cognitive Impairment, Alzheimer Dementia
Effects of Muscle Relaxation on Cognitive Function in Patients With Mild Cognitive Impairment and Early Stage Dementia.
Muscle relaxation has been reported to be effective in alleviating anxiety and agitation symptoms in patients with dementia, but no studies have examined the effects of muscle relaxation therapy on cognitive function changes.
- Trial name
- NCT03507192
- Testing
- Muscle relaxation using full body massage machine
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Samsung Medical Center
Alzheimers Disease
A Clinical Trial of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 2 (NCT07170150)
- Testing
- Trontinemab
- Where
- 147 sites in United States, Argentina and 14 more
- Volunteers
- 1,060 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease, Mild Cognitive Impairment
Korean Brain Aging Study for Early Diagnosis and Prediction of Alzheimer's Disease
This is a prospective cohort study for cognitively normal (young and old), mild cognitive impairment, and Alzheimer's disease people
- Trial name
- KBASE (NCT02137460)
- Where
- South Korea
- Volunteers
- 721 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Alzheimer Disease, Early Onset
A Pivotal Study of LIPUS-Brain in Patients With Early Alzheimer's Disease
This study is a multicenter, randomized, double-blinded, placebo-controlled Phase 3 study comparing LIPUS-Brain transcranial low-intensity pulsed-wave ultrasound device to placebo in patients with Early Alzheimer's Disease.
- Trial name
- NCT05983575
- Testing
- LIPUS-Brain
- Where
- 19 sites in Japan
- Volunteers
- 220 people
- Sponsor
- Sound Wave Innovation CO., LTD.
Cognition Disorders, Alzheimer Disease
Treatment for Early Memory Loss
The purpose of this study is to evaluate the effectiveness of donepezil (Aricept) for the treatment of mild cognitive impairment (MCI) in elderly adults.
- Trial name
- NCT00042172
- Testing
- Donepezil, Ginkgo Biloba Extract
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Iowa
Early Alzheimer´s Disease
A Research Study Investigating Semaglutide in People With Early Alzheimer's Disease (EVOKE Plus)
This study is done to find out whether the medicine, semaglutide, has a positive effect on early Alzheimer's disease. Participants will either get semaglutide or placebo (a "dummy" medicine which does not contain any study…
- Trial name
- EVOKE Plus (NCT04777409)
- Testing
- Semaglutide
- Where
- 498 sites in United States, Argentina and 36 more
- Volunteers
- 1,840 people
- Sponsor
- Novo Nordisk A/S
Mild Cognitive Impairment, Cognitive Impairment
SNIFF - 3-Week Aptar CPS Device
The SNIFF 3-Week Aptar Device study will involve using a device to administer insulin or placebo through each participant's nose or intra-nasally. Insulin is a hormone that is produced in the body.
- Conditions
- Mild Cognitive Impairment, Cognitive Impairment, Alzheimer Disease, Early Onset
- Trial name
- NCT05006599
- Testing
- Insulin (Humulin® R U-100), Aptar Pharma CPS Intranasal Delivery Device
- Volunteers
- healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Alzheimer's Disease
Reminiscence, Anxiety and Early Alzheimer's Disease
This study seeks to establish the acceptability and evaluate the limited efficacy of Simple Reminiscence (SR), a home-delivered non-pharmacological intervention designed to relieve stress, improve affect, and prevent or quell…
- Trial name
- NCT02319681
- Testing
- Simple Reminiscence (SR), Attention Control (AC)
- Where
- United States
- Volunteers
- healthy volunteers welcome
- Sponsor
- Emory University
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Alzheimers Disease
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
- Trial name
- TRONTIER 1 (NCT07169578)
- Testing
- Trontinemab
- Where
- 142 sites in United States, Argentina and 11 more
- Volunteers
- 1,101 people
- Sponsor
- Hoffmann-La Roche
Alzheimer's Disease
A 24-Month Study to Evaluate the Efficacy and Safety of Elenbecestat (E2609) in Participants With Early Alzheimer's Disease
The name of this trial is MissionAD1. This phase 3 study consists of a Core and Open Label Extension (OLE) Phase in participants with Early Alzheimer's Disease (EAD), and will be conducted to evaluate the efficacy and safety of…
- Trial name
- MissionAD1 (NCT02956486)
- Testing
- Elenbecestat
- Where
- 258 sites in United States, Argentina and 16 more
- Volunteers
- 2,212 people
- Sponsor
- Eisai Co., Ltd.
Alzheimer Dementia
Allopregnanolone Regenerative Therapeutic for Early Alzheimer's Disease: Intramuscular Study
The purpose of this study is to identifying the intramuscular dose equivalent to the 4mg intravenous dose and assess its safety and tolerability as a weekly injection.
- Trial name
- Allo-IM (NCT03748303)
- Testing
- Allopregnanolone
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- University of Arizona
Multiple Myeloma
Detecting Early Myocardial Infiltration w/Amyloid & Light Chain Deposition Disease in Multiple Myeloma Subjects
The purpose of this study is to see if MRI techniques can be used for early evaluation of cardiac amyloidosis which is sometimes seen in individuals with multiple myeloma.
- Trial name
- NCT01018927
- Testing
- Administering three additional MRI images
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Arkansas